News | December 17, 2024
SPARC signs LoI with UCSF and Tiller Therapeutics for pre-clinical oncology asset and associated IP
SPARC to receive 55% equity in Tiller Therapeutics
SPARC to receive 55% equity in Tiller Therapeutics
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India
Subscribe To Our Newsletter & Stay Updated
